{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-121219","form_type":"8-K","ticker":null,"cik":"0001733294","company_name":"Generation Bio Co.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.276595+00:00","generated_at":"2026-05-16T13:14:20.090924+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"XOMA Royalty to acquire Generation Bio for $4.2913/share plus CVR tied to Moderna deal","bullets":["Cash consideration of $4.2913 per share plus one non-transferable CVR per share; CVR payments from net cash >$29M, lease savings, Moderna milestones/royalties, and ctLNP platform licensing.","Tender offer expected to close in February 2026; condition requires at least a majority of shares tendered; support agreements cover ~15% of outstanding shares.","CVR holders receive up to 90% of Moderna collaboration proceeds (years 1-3) and up to 70% of platform licensing proceeds (years 1-2), declining over 10-year period.","Generation Bio Board unanimously approved; termination fee of $840k payable by Generation Bio under certain circumstances.","Acquisition provides XOMA Royalty with potential milestone and royalty payments from Generation Bio's existing Moderna collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-121219","json":"https://secwatch.observer/filing/0001104659-25-121219.json","markdown":"https://secwatch.observer/filing/0001104659-25-121219.md","text":"https://secwatch.observer/filing/0001104659-25-121219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733294/000110465925121219/0001104659-25-121219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733294/000110465925121219/gbio-20251215x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:14:20.090924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a87d52fbdf5064c35d55462ba1ca94d1cc46bc10","claim":"Generation Bio Co. entered into Agreement and Plan of Merger with XOMA Royalty Corporation (Parent) and XRA 7 Corp. (Merger Sub) (effective 2025-12-15).","evidence_excerpt":"On December 15, 2025, Generation Bio Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with XOMA Royalty Corporation, a Nevada corporation (“Parent”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733294/000110465925121219/0001104659-25-121219-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"XOMA Royalty Corporation (Parent) and XRA 7 Corp. (Merger Sub)"},{"label":"Effective","value":"2025-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}